Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HSV-2 vaccine
- Development stage
- Preclinical
- Lead developer
- Auro Vaccines
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PBS Vax HSV-2 Vaccine is a therapeutic vaccine candidate developed by Auro Vaccines for the treatment of Herpes Simplex Virus Type 2 (HSV-2) infection. The vaccine utilizes a heterologous prime-boost strategy, consisting of a GeneVax DNA vaccine prime followed by a VesiculoVax viral vector boost. This approach is designed to induce robust and durable T-cell and antibody responses against HSV-2 antigens. As of the latest pipeline updates, the program is in the preclinical stage and is currently listed as being on hold.
- Brand names
- PBS Vax
- Other names
- HSV-2 vaccineHSV2 vaccineHSV 2 vaccinePBS Vax HSV-2 VaccineGeneVax prime / VesiculoVax boost HSV-2 vaccine
Beyond the preview
Go deeper on HSV-2 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HSV-2 vaccine.